Gene silencing approaches for the treatment of Huntington's disease

Médecine sciences : M/S
Nicolas Merienne, Nicole Déglon

Abstract

Huntington's disease is a rare neurodegenerative disease caused by a pathologic CAG expansion in the exon 1 of the huntingtin (HTT) gene. Aggregation and abnormal function of the mutant HTT (mHTT) cause motor, cognitive and psychiatric symptoms in patients, which lead to death in 15-20 years. Currently, there is no treatment for HD. Experimental approaches based on drug, cell or gene therapy are developed and reach progressively to the clinic. Among them, mHTT silencing using small non-coding nucleic acids display important physiopathological benefit in HD experimental models.

References

Nov 1, 1985·Journal of Neuropathology and Experimental Neurology·J P VonsattelE P Richardson
Mar 22, 2005·Nature Biotechnology·Adam D JudgeIan MacLachlan
Apr 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Scott Q HarperBeverly L Davidson
Jul 16, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Edgardo Rodriguez-LebronRonald J Mandel
Aug 13, 2005·Neuroscience Research·Yu-Lai WangIchiro Kanazawa
Sep 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Kum-Joo ShinIain D C Fraser
Nov 15, 2006·Médecine sciences : M/S·Frédéric Saudou, Sandrine Humbert
Nov 15, 2006·Médecine sciences : M/S·Annick Harel-Bellan
Jan 24, 2007·Lancet·Francis O Walker
Mar 16, 2007·Neuron·Beverly L Davidson, Ryan L Boudreau
Oct 18, 2007·Proceedings of the National Academy of Sciences of the United States of America·M DiFigliaN Aronin
Apr 5, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nicholas R FranichDeborah Young
Feb 26, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ryan L BoudreauBeverly L Davidson
Mar 18, 2009·Experimental Neurology·Maria Stella LombardiWilliam F Kaemmerer
Apr 1, 2009·Annals of Neurology·Valérie DrouetNicole Déglon
May 5, 2009·Médecine sciences : M/S·Laetitia AubryAnselme L Perrier
Mar 24, 2010·Brain Research·Ryan L Boudreau, Beverly L Davidson
Dec 18, 2010·Lancet Neurology·Christopher A Ross, Sarah J Tabrizi
Feb 3, 2011·The Journal of Clinical Investigation·Dinah W Y Sah, Neil Aronin
Feb 15, 2011·Neuron·Zachary R Crook, David Housman
Oct 18, 2011·Neurobiology of Disease·Thomas B LentzR Jude Samulski
Oct 28, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jodi L McBrideBeverly L Davidson
Dec 2, 2011·Médecine sciences : M/S·Fabien GosseletLaurence Fenart
Dec 14, 2011·Gene Therapy·Y Zhang, R M Friedlander
Aug 28, 2012·Chemistry & Biology·Glen F Deleavey, Masad J Damha
Oct 3, 2012·Trends in Molecular Medicine·Amber L SouthwellMichael R Hayden
Oct 30, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Katia YoussovAnne-Catherine Bachoud-Lévi
May 8, 2014·Médecine sciences : M/S·David AdamsVincent Algalarrondo

❮ Previous
Next ❯

Citations

Oct 17, 2017·Human Gene Therapy·Françoise PiguetNathalie Cartier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Antisense Oligonucleotide Therapies: ND

Antisense oligonucleotides are synthetic DNA oligomers that hybridize to a target RNA. This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.